Chidamide

(Tucidinostat)

Epigenetic modulator
Immunomodulator
Subtype-selective HDACi
(HDAC 1,2,3,10)

• Peripheral T-cell lymphoma
  （Refractory Relapse）

• Breast cancer
  (HR+/combined with AI)

• DLBCL
  (First-line/combined with SOC)

• Non-small cell lung cancer
  （PD-1 resistant/combined with PD-L1）

• Non-small cell lung cancer
  （First-line/combined with PD-1）

• 2013.02
• 2018.11

• 2014.12
• 2019.11

Chiglitazar Sodium

(Carfloglitazar)

Novel insulin sensitizers
Non-TZD configuration restricted PPAR
Pan agonists

• Type 2 diabetes
  （Poor diet & exercise control）

• Type 2 diabetes
  （Combined with Metformin）

• Non-alcoholic steatohepatitis

• 2019.09

• 2021.10

Chiauranib

Three-way targeted kinase inhibitor
（Auroa B/VEGFRs/
CSF1R）

• Small cell lung cancer
  （Third-Line/Monotherapy）

• Small cell lung cancer
  （Third-Line/Monotherapy, USA）

• Ovarian caner
  （Resistance to Platinum/in combination with chemotherapy）

• Liver cancer
  (Second-line/monotherapy)

• Lymphoma
  （Monotherapy/in combination with Chidamide）

• Triple negative breast cancer
  （Monotherapy & combined therapy）

CS23546

Small-Molecule PD-L1 Inhibitor

PD-L1 dimer antagonist

• Tumor/Immune system disorders

CS231295

Brain-Penetrant Aurora B Selective Inhibitor

Brain penetrating AuroraB inhibitor

• Healthy Subjects
  （Tolerability & PK/PK study）

• Rheumatoid arthritis

• Other autoimmune diseases
  （Multiple sclerosis/Inflammatory bowel disease/Alopecia areata/Systemic lupus erythematosus/Idiopathic dermatitis/Graft versus host disease, etc.）

CS32582

Highly Selective Small-Molecule Allosteric Inhibitor of Tyrosine Kinase 2 (TYK2)

TYK2 selective inhibitors

• Autoimmune diseases

Other Pipeline Products